301207 Stock Overview
Engages in the research, development, production, and sale of vaccines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 301207 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Hualan Biological Vaccine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.08 |
| 52 Week High | CN¥28.03 |
| 52 Week Low | CN¥15.42 |
| Beta | 0.79 |
| 1 Month Change | -5.44% |
| 3 Month Change | 12.16% |
| 1 Year Change | -34.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301207 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.0% | -3.0% | -2.1% |
| 1Y | -34.3% | -19.0% | 9.8% |
Return vs Industry: 301207 underperformed the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 301207 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 301207 volatility | |
|---|---|
| 301207 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 301207 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301207's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 770 | Wenjue An | www.hualanbacterin.com |
Hualan Biological Vaccine Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, influenza A (H1N1) virus split vaccines, ACYW135 group meningococcal polysaccharide vaccines, recombinant hepatitis B vaccines, group A and C meningococcal polysaccharide vaccines, freeze-dried human rabies vaccine, and tetanus vaccines, as well as genetic engineering of biological products. The company also sells self-produced products.
Hualan Biological Vaccine Inc. Fundamentals Summary
| 301207 fundamental statistics | |
|---|---|
| Market cap | CN¥10.76b |
| Earnings (TTM) | CN¥497.61m |
| Revenue (TTM) | CN¥1.65b |
21.6x
P/E Ratio6.5x
P/S RatioIs 301207 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301207 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.65b |
| Cost of Revenue | CN¥364.32m |
| Gross Profit | CN¥1.29b |
| Other Expenses | CN¥787.59m |
| Earnings | CN¥497.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.84 |
| Gross Margin | 77.91% |
| Net Profit Margin | 30.17% |
| Debt/Equity Ratio | 4.9% |
How did 301207 perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield72%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:28 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hualan Biological Vaccine Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yizheng Yang | China International Capital Corporation Limited |
| Kai Wang | Citic Securities Co., Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |